Table 2.
Disease severity reported as mean scores for EASI, BSA, POEM, itch-NRS, sleep-NRS, pain-NRS, and DLQI, at baseline, Week 16, Week 32, and Week 48. Disease severity assessed throughout the observation period in the overall population and in the two sub-cohorts of patients treated with either 30 mg or 15 mg upadacitinib
| Overall population | 30 mg upadacitinib sub-cohort | 15 mg upadacitinib sub-cohort | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Ntot = 146 |
Week 16 Ntot = 125 |
Week 32 Ntot = 113 |
Week 48 Ntot = 97 |
p value | Baseline Ntot = 118 |
Week 16 Ntot = 101 |
Week 32 Ntot = 90 |
Week 48 Ntot = 77 |
p value | Baseline Ntot = 28 |
Week 16 Ntot = 24 |
Week 32 Ntot = 23 |
Week 48 Ntot = 20 |
p value | |
| EASI (mean±SD) | 25.0 ± 11.2 | 5.4 ± 7.9 | 2.0 ± 3.1 | 2.6 ± 4.1 | < 0.001 | 24.9 ± 12.0 | 5.1 ± 7 | 2.2 ± 3.4 | 2.6 ± 4.2 | < 0.001 | 25.6 ± 7.2 | 6.9 ± 11 | 1.41 ± 1.9 | 2.7 ± 3.7 | < 0.001 |
| BSA (mean ± SD) | 32.5 ± 23.4 | 8.8 ± 15.9 | 4.2 ± 7.4 | 3.6 ± 6.3 | < 0.001 | 33.4 ± 24.0 | 9.1 ± 17.0 | 4.5 ± 7.9 | 3.7 ± 6.6 | < 0.001 | 28.8 ± 20.7 | 7.5 ± 9.9 | 3.13 ± 4.8 | 3.1 ± 5.1 | < 0.001 |
| DLQI (mean ± SD) | 16.3 ± 8.6 | 4.2 ± 6.3 | 2.3 ± 3.8 | 2.5 ± 4.0 | < 0.001 | 15.5 ± 8.6 | 3.9 ± 5.8 | 2.3 ± 4.0 | 2.6 ± 4.1 | < 0.001 | 19.6 ± 7.8 | 5.6 ± 8.3 | 2 ± 3.1 | 2.3 ± 3.5 | < 0.001 |
| POEM (mean ± SD) | 18.3 ± 8.1 | 5.9 ± 8.6 | 3.0 ± 4.3 | 3.0 ± 4.9 | < 0.001 | 18 ± 8.2 | 5.8 ± 8.8 | 3.2 ± 4.6 | 3.2 ± 5.1 | < 0.001 | 19.7 ± 7.7 | 6 ± 7.8 | 1.96 ± 2.5 | 2.5 ± 4.1 | < 0.001 |
| Itch-NRS (mean ± SD) | 7.1 ± 2.8 | 1.8 ± 2.4 | 1.3 ± 2.0 | 1.4 ± 2.1 | < 0.001 | 6.9 ± 2.9 | 1.7 ± 2.1 | 1.3 ± 2.1 | 1.4 ± 2.1 | < 0.001 | 7.8 ± 2.3 | 2.3 ± 3.5 | 1.17 ± 1.7 | 1.2 ± 2.3 | < 0.001 |
| Sleep-NRS (mean ± SD) | 5.5 ± 3.4 | 1.1 ± 2.2 | 0.7 ± 1.7 | 0.9 ± 1.8 | < 0.001 | 5.4 ± 3.5 | 1.0 ± 1.9 | 0.8 ± 1.8 | 1 ± 2.0 | < 0.001 | 6.3 ± 3.0 | 1.7 ± 3.3 | 0.3 ± 1.2 | 0.3 ± 0.8 | ≤ 0.001 |
| Pain-NRS (mean ± SD) | 3.5 ± 3.8 | 0.7 ± 1.8 | 0.3 ± 1.3 | 0.2 ± 0.9 | < 0.001 | 3.9 ± 3.9 | 0.8 ± 1.8 | 0.4 ± 1.4 | 0.3 ± 1.0 | < 0.001 | 2.0 ± 3.3 | 0.5 ± 1.9 | 0 ± 0 | 0.1 ± 0.4 | 0.03 |
BSA body surface area, DLQI Dermatology Life Quality Index, EASI Eczema Area and Severity Index, NRS numeric rating scale, Ntot total number, POEM Patient Oriented Eczema Measure, SD standard deviation
The within groups comparisons were performed by Wilcoxon rank test for dependent observations. The p values reported in the columns refer to the highest p value of all pairwise comparisons